Glucagon-like peptide-1 (GLP-1) peptides have emerged as a compelling therapeutic target for managing metabolic syndromes. These naturally occurring molecules are secreted by the gut in response to meal intake, stimulating insulin production and suppressing glucagon secretion. GLP-1 agents possess promising therapeutic outcomes in treating type 2 d